Mumbai: Patients who are very sick – 19 patients fate better when they receive remdesivir and tovilizumab, two experimental drugs are given individually or in combination, than those who do not get it, observe doctors from KEM Hospital and the main medical hospital.
The survival rate in patients who receive one or both drugs is 64%; It dropped to 34% among those who did not get both.
In a group of benefits, the rate of release between which was only given remdesivir was 66%, for those who only suffered from Tovilizumab was 80%, and 47% among those combined with the two drugs.
Read also only guiding patients who need where medicines that save life: Sonu Sood told Bombay Hcmumbai: The Bombay High Court on Tuesday said that he would hear the actor Sonu Sood on the intervention in the litigation of public interests where he was accused of injection of remediesivir and Todilizumab Distributed respond to social media requests.
Judicial head bench Datta Datta and doctors studied the effects of remedyivir and Tovilizumab in 521 patients at KEM Hospital and compare it with retrospective clinical details of 214 patients from a time when they were not available as experimental drugs for Covid (from March 23 to 31 May 2020).
Of 334 (64%) patients run out after being given or both drugs, only five additional oxygen needed.
The doctor’s observational study was published on July 1 in the Journal of the Associent of Indian Doctors.
The doctors found that hospitalization (average day) maximum in the Tocilizumab group – 47 days.
It was 14 days in the Remdesivir group and 10 in groups that received both drugs.
Patients who need a vasopressor, drugs that help tighten blood vessels and increase blood pressure, have higher mortality, said Dr.
Vishal Gupta, Associate Professor, intensive care, the Ministry of Medicine, from the hospital and the main research investigator.
Also read the 2nd wave of EBBS, the case of mukormycosis, the decline in mortality at the Mumbaocity Hospital has witnessed a significant decline in the case of mukormycosis after a large burst over the past two months.
The hospital said there was a decrease marked in reception – both local and through reference – in the last 10-15 days.
“The study of observing that patients under 55 years about three times more likely to run out.
Patient opportunities with facial masks or nasal branches that survive are 34 times higher than those in invasive ventilation,” said Dr Sushrut Ingawale, a third year resident , who worked on research with Dr.
Amit Bhondve, Dr.
Wasim Khot and nine others.
However, most of these factors do not apply to the Tocilizumab group.
“We observed that Tocedazumab, if given at the right time for the right patient, it can help in increasing survival and less requires mechanical ventilation.
In old and fragile patients, it does not seem to have similar results.
For example, this drug may not increase results For patients who already have secondary infections, “Gupta said.
Read Alsomumbai: Infection seen among HIV patients prey on Covid survivoursuursu, which usually affects those with a very suppressed immune system such as people living with HIV / AIDS or organ transplant patients, increasingly seen in patients who have recovered from Covid-19.
In particular, many contracted this rare co-infection even though it was not ‘bombing’ “our study stated that these drugs could provide better clinical results, but larger multi-centric trials needed,” Ingawale added.
Being a tertiary care hospital, Most of the majority received critical patients.
The researchers classified 521 patients in three random treatment groups based on the availability and supply of two drugs between June 1 and September 3020, and comparing it to the fourth group, claiming to the ICU when these drugs were not available.
More than half of patients above 55, men (62%), with diabetes (41.8%) and hypertension (42.4%) as the most common comorbidity.